ClinConnect ClinConnect Logo
Search / Trial NCT06717854

Retrograde and Antegrade Enema for Prevention of LARS After LAR: a Randomized Controlled Trial

Launched by SICHUAN CANCER HOSPITAL AND RESEARCH INSTITUTE · Nov 30, 2024

Trial Information

Current as of July 24, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying whether two types of enemas—antegrade and retrograde—can help prevent a condition called Low Anterior Resection Syndrome (LARS) in adults who have had surgery for rectal cancer. LARS can cause issues with bowel function and affect quality of life after surgery. Researchers want to find out if these enemas can improve bowel function, sleep quality, and overall well-being after surgery compared to the standard care, which involves no enema.

To participate in this study, you need to be at least 18 years old and have been diagnosed with primary rectal adenocarcinoma. You should also have undergone surgery for rectal cancer with a temporary ileostomy. If you join, you will receive either an antegrade enema, a retrograde enema, or standard care about one month after your surgery. During the study, you'll keep a diary to track your symptoms. The trial is not yet recruiting participants, but it aims to help improve the lives of patients recovering from rectal cancer surgery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Based on the NCCN guidelines for the pathological diagnosis of rectal cancer, patients are identified as having Primary Rectal Adenocarcinoma.
  • ≥18 years.
  • For the first time, anterior rectal dissection combined with prophylactic ileostomy was performed using laparoscopic, robotic, and open techniques.
  • The patient exhibits normal cognitive and expressive abilities.
  • Informed consent was obtained for voluntary participation in the study.
  • Exclusion Criteria:
  • American Society of Anesthesiologists (ASA) Class III or higher.
  • A combination of other intestinal conditions, including inflammatory bowel disease and Crohn's disease.
  • Mental disorders and prolonged use of psychotropic medications.
  • The presence of contraindications to enema administration.

About Sichuan Cancer Hospital And Research Institute

Sichuan Cancer Hospital and Research Institute is a leading comprehensive cancer treatment and research facility located in Chengdu, China. Renowned for its commitment to advancing oncology, the institute integrates clinical practice with cutting-edge research to develop innovative treatment protocols and enhance patient care. With a multidisciplinary team of experts, the hospital focuses on a wide range of cancer therapies, including surgical, medical, and radiation oncology, while also actively participating in clinical trials to contribute to the global understanding of cancer management. Its state-of-the-art facilities and dedication to research make it a pivotal player in the fight against cancer in the region and beyond.

Locations

Chengdu, Sichuan, , China

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported